Merck & Co., Inc. (MRK) announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ...

[4] Epidermal growth factor receptor antagonism can ... positive results in other tumors are the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) pathway.

The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic ...

Merck ( MRK, Financials) stated that sacituzumab tirumotecan (sac-TMT) was designated a Breakthrough Therapy by the FDA for advanced or metastatic nonsquamous non-small cell lung cancer with epidermal ...

Merck (MRK) announced that the U.S. FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for the treatment of patients ...

Janux Therapeutics' pipeline includes janx007, a tumor-activated T cell engager (TRACT) that targets prostate-specific ...

Dysregulated cell signaling underlies various diseases, emphasizing the importance of understanding these pathways for ...

In this study, we demonstrated the protective role of hair follicle-specific epidermal growth factor receptor (EGFR) against scarring hair follicle destruction. Mechanistically, disruption of EGFR ...

NewsVoir Mumbai Maharashtra [India]2 Lung cancer remains one of the most prevalent and deadly cancers globally with approximately 22 million new cases diagnosed annually contributing to 18 of all canc ...